For the Nine-Month Period ended December 31, 2005 (Fiscal Year ending March 31, 2006)

## Company name: NIPRO CORPORATION

Code No.:8086 TSE/OSE-1st Section

## (URL: http://www.nipro.co.jp/)

Representative: Minoru Sano, President and Representative Director
Contact: Akihiko Yamabe, Director, General Manager of Accounting \& Corporate Planning Division
TEL (06) 6372-2331

1. Matters related to the preparation of quarterly financial summary
(1)Adoption of simplified accounting treatments: N/A
(2)Difference in the method of accounting treatment from the most recent fiscal year:

Accounting standard for impairment of fixed asset has been adopted since this accounting period.
(3)Changes in the scope of consolidation and application of the equity method: Adoption
(Content: Consolidation (New) 4)
2. Business results and financial position for the nine months ended December 31, 2005 of the Fiscal Year ending March 31,2006.(From April 1, 2005 to December 31, 2005)
(1)Results of Operations (Note: Amounts are rounded off per one million yen)

|  | Net Sales |  | Operating Income |  | Recurring Income |  | Net (Quarter) Income |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% |
| Nine months ended | 156,047 |  | 10,573 | 15.5 | 10,957 | 37.6 | 4,610 | (1.6) |
| December 31, 2005 |  |  |  |  |  |  |  |  |
| Nine months ended December 31, 2004 | 145,732 |  | 9,158 | (9.0) | 7,964 | (1.1) | 4,684 | 20.4 |
| Fiscal Year ended March 31, 2005 | 192,320 |  | 10,404 |  | 8,685 |  | 4,518 |  |


|  | Basic Earnings <br> per Share | Diluted Earnings <br> per Share |
| :--- | :---: | :---: |
| Nine months ended <br> December 31, 2005 | 72.55 | Yen |
| Nine months ended <br> December 31, 2004 | 73.65 | - |
| Fiscal Year ended <br> March 31, 2005 | 69.37 | - |

(Note) Percentage for net sales, operating income, etc. represents the ratio of change from the same period of the previous fiscal year.
[Supplementary information on the consolidated results of operations]
The situation of Japanese economy for this nine-month period generally remained in the trend of gradual recovery supported by the firm growth of capital investments and individual consumptions as a result of the improvement of corporate earnings. At the same time it still remained unpredictable, since US Dollar indicated its weakness in the exchange market in addition to the decelerating of overseas economy and high crude oil price. Under such circumstances, Nipro Corporation continuously strived to develop new products and focused on reinforcement of production capacity and sales capability in order to improve the business performance.

As a result, net sales for the nine months ended December 31, 2005 increased by $7.1 \%$ from the same period of the previous fiscal year to 156,072 million yen. Operating income increased by $15.5 \%$ from the same period of the previous fiscal year to 10,573 million yen and recurring income increased by 37.6\% from the same period of the previous fiscal year to 10,957 million yen.

Net income decreased, due to the loss on impairment of fixed assets, by $1.6 \%$ to 4,610 million yen from the same period of the previous fiscal year.
(2)Financial Position

|  | Total Assets | Shareholders' <br> Equity | Ratio of Shareholders' <br> Equity to Total Assets | Shareholder' Equity <br> per Share |
| :--- | :---: | :---: | :---: | :---: |
| Nine months ended <br> December 31, 2005 | Millions of yen | Millions of yen | \% | yen <br> Nine months ended <br> December 31, 2004 |
| Fiscal Year ended <br> March 31, 2005 | 292,635 | 108,825 | 33.2 | $1,712.78$ |

Cash Flows

|  | Cash flows from <br> operating activities | Cash flows from <br> investing activities | Cash flows from <br> financing activities | Cash and cash <br> equivalents |
| :--- | :---: | :---: | :---: | :---: |
| Nine months ended <br> December 31, 2005 | Millions of yen | Millions of yen | Millions of yen | Millions of yen <br> Nine months ended <br> December 31, 2004 |
| 3,092 | $(21,064)$ | 8,362 | 45,166 |  |
| Fiscal Year ended <br> March 31,2005 | 9,163 | $(9,512)$ | 10,666 | 52,638 |

[Supplementary information on the changes in the financial position]
(1)Changes in the financial position

Total assets increased by 33,887 million yen to 327,635 million yen from the end of previous fiscal year.
Current assets increased by 4,372 million yen to 139,738 million yen and fixed assets increased by 29,514 million yen to 187,897 million yen from the end of previous fiscal year. Fixed assets increased mainly due to the increase in investment securities by 21,251 million yen.

Shareholders' equity increased by 12,124 million yen from the end of previous fiscal year, mainly due to the rise in valuation difference of other securities by 9,501 million yen.
(2)Cash flows

Net cash provided by operating activities was 3,092 million yen, net cash used in investing activities was 21,064 million yen, net cash provided by financing activities was 8,362 million yen. As a result, cash and cash equivalents at the end of the period amounted to 45,166 million yen.

Net cash used in investing activities was mainly spent in acquisition of fixed assets for 14,331 million yen and investment securities for 9,501 million yen, net cash provided by financing activities was mainly owing to the long-term borrowing for 10,510 million yen.
(Reference)
Consolidated Business Forecasts for the Fiscal Year ending March 31, 2006 (From April 1, 2005 to March 31, 2006)

|  | Sales | Recurring Income | Net Income |
| :--- | :---: | :---: | ---: |
| Fiscal Year ending | Millions of yen | Millions of yen | Millions of yen |
| March 31, 2006 | 205,000 | 10,500 | 4,400 |

(Reference) Projected Earnings per Share for the Fiscal Year ending March 31, 2006: 67.56 yen
[Supplementary information on the business forecasts]
The business environment is anticipated to remain severe due to the concern of risks in persisting high crude oil price and proceeding weakness of US Dollar. Nipro Corporation, however, continuously endeavors to develop new products, as well as to reinforce the production capacity and sales capability in order to improve the business performance.

There is no amendment to the forecasts announced on November 21, 2005.
※The above forecasts are based on the information available to the management as of the date of this report. The actual results may differ from these forecasts due to various factors occurring hereafter.

## Consolidated Balance Sheets

| Account Period | As ofDecember 31, 2005 |  | As ofMarch 31, 2005 |  | Increase (decrease) | As ofDecember 31, 2004 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% | Amount | \% | Amount | Amount | \% |
| (ASSETS) |  |  |  |  |  |  |  |
| Current assets | 139,738 | 42.7 | 135,365 | 46.1 | 4,372 | 138,851 | 47.5 |
| Cash on hand and bank deposits | 47,911 |  | 56,153 |  | $(8,242)$ | 55,958 |  |
| Trade notes and accounts receivable | 46,848 |  | 40,144 |  | 6,703 | 43,341 |  |
| Inventories | 39,471 |  | 33,649 |  | 5,822 | 33,316 |  |
| Deferred tax assets | 1,672 |  | 2,203 |  | (531) | 1,851 |  |
| Others | 4,160 |  | 3,423 |  | 736 | 4,706 |  |
| Allowance for doubtiul accounts | (325) |  | (209) |  | (115) | (322) |  |
| Fixed assets | 187,897 | 57.3 | 158,383 | 53.9 | 29,514 | 153,723 | 52.5 |
| Tangible fixed assets | 106,654 | 32.5 | 98,788 | 33.6 | 7,866 | 98,213 | 33.6 |
| Buildings and structures | 44,195 |  | 40,718 |  | 3,477 | 41,527 |  |
| Machinery, equipment and vehicles | 27,916 |  | 23,990 |  | 3,925 | 23,563 |  |
| Land | 23,143 |  | 22,839 |  | 303 | 22,836 |  |
| Construction in progress | 6,902 |  | 7,232 |  | (329) | 6,135 |  |
| Others | 4,496 |  | 4,007 |  | 488 | 4,150 |  |
| Intangible fixed assets | 1,102 | 0.3 | 941 | 0.3 | 160 | 912 | 0.3 |
| Consolidation adjustments | 108 |  | 2 |  | 106 | 2 |  |
| Others | 993 |  | 939 |  | 53 | 910 |  |
| Investments and other assets | 80,140 | 24.5 | 58,653 | 20.0 | 21,487 | 54,596 | 18.6 |
| Investment securities | 62,957 |  | 41,706 |  | 21,251 | 37,817 |  |
| Long-term loans receivable | 2,340 |  | 2,459 |  | (119) | 2,483 |  |
| Deferred tax assets | 531 |  | 238 |  | 293 | 208 |  |
| Lease deposits | 11,411 |  | 11,513 |  | (102) | 11,619 |  |
| Others | 3,546 |  | 3,465 |  | 80 | 3,098 |  |
| Allowance for doubtful accounts | (647) |  | (730) |  | 83 | (630) |  |
| Total assets | 327,635 | 100.0 | 293,748 | 100.0 | 33,887 | 292,575 | 100.0 |

(Note) Increase (decrease) represents the comparison between December 31, 2005 and March 31, 2005.

## Consolidated Balance Sheets

| Period | As ofDecember 31, 2005 |  | As ofMarch 31, 2005 |  | Increase (decrease) | $\begin{array}{c\|} \hline \text { As of } \\ \text { December 31, 2004 } \end{array}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% | Amount | \% | Amount | Amount | \% |
| (LIABILITIES) |  |  |  |  |  |  |  |
| Current liabilities | 119,048 | 36.3 | 96,241 | 32.7 | 22,806 | 94,465 | 32.3 |
| Trade notes and accounts payables | 32,209 |  | 29,084 |  | 3,124 | 30,415 |  |
| Shorts-term borrowings | 46,691 |  | 40,443 |  | 6,247 | 41,390 |  |
| Current portion of bonds | 13,020 |  | 3,000 |  | 10,020 |  |  |
| Other payables | 4,436 |  | 4,614 |  | (178) | 4,123 |  |
| Accrued Income taxes | 2,192 |  | 3,493 |  | $(1,300)$ | 2,880 |  |
| Accrued bonuses | 1,101 |  | 1,405 |  | (304) | 1,199 |  |
| Notes payables for plant and equipment | 6,665 |  | 2,936 |  | 3,728 | 4,046 |  |
| Commercial paper | 9,000 |  | 7,000 |  | 2,000 | 7,000 |  |
| Others | 3,731 |  | 4,262 |  | (531) | 3,409 |  |
| Fixed liabilities | 98,131 | 30.0 | 99,198 | 33.8 | $(1,067)$ | 102,988 | 35.2 |
| Bonds | 16,040 |  | 26,000 |  | $(9,960)$ | 29,000 |  |
| Convertible-bond type bonds with stock acquisition rights | 14,000 |  | 14,000 |  |  | 14,000 |  |
| Long-term borrowings | 48,950 |  | 46,183 |  | 2,767 | 48,666 |  |
| Deferred tax liabilities | 12,639 |  | 6,753 |  | 5,886 | 5,190 |  |
| Accrued pension and severance cost | 3,079 |  | 2,867 |  | 211 | 2,684 |  |
| Others | 3,421 |  | 3,393 |  | 28 | 3,446 |  |
| Total Liabilities | 217,179 | 66.3 | 195,439 | 66.5 | 21,739 | 197,453 | 67.5 |
| (MINORITY INTERESTS) Minority interests | 1,631 | 0.5 | 1,608 | 0.6 | 23 | 1,550 | 0.5 |
| (SHREHOLDERS' EQUITY) |  |  |  |  |  |  |  |
| Capital | 28,663 | 8.8 | 28,663 | 9.8 |  | 28,663 | 9.8 |
| Capital surplus | 29,972 | 9.1 | 29,972 | 10.2 |  | 29,972 | 10.2 |
| Earned surplus | 34,643 | 10.6 | 32,181 | 10.9 | 2,461 | 32,347 | 11.1 |
| Valuation difference of other securities | 22,261 | 6.8 | 12,759 | 4.3 | 9,501 | 10,340 | 3.5 |
| Foreign currency translation adjustment | $(6,079)$ | (1.9) | $(6,289)$ | (2.1) | 209 | $(7,197)$ | (2.4) |
| Treasury stock | (634) | (0.2) | (586) | (0.2) | (48) | (554) | (0.2) |
| Total Shareholders' equity | 108,825 | 33.2 | 96,700 | 32.9 | 12,124 | 93,571 | 32.0 |
| Total Liabilities, minority Interests and shareholders' equity | 327,635 | 100.0 | 293,748 | 100.0 | 33,887 | 292,575 | 100.0 |

(Note) Increase (decrease) represents the comparison between December 31, 2005 and March 31, 2005.

## Consolidated Statements of Income

(Unit: Millions of yen)

| Account | Nine months ended December 31,2005 |  | Nine months ended December 31,2004 |  | Increase (decrease) | Fiscal year ended March 31,2005 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% | Amount | \% | Amount | Amount | \% |
| Net sales | 156,047 | 100.0 | 145,732 | 100.0 | 10,314 | 192,320 | 100.0 |
| Cost of sales | 112,487 | 72.1 | 105,422 | 72.3 | 7,065 | 140,072 | 72.8 |
| Gross profit | 43,559 | 27.9 | 40,310 | 27.7 | 3,249 | 52,247 | 27.2 |
| Selling, general and administrative expenses | 32,986 | 21.1 | 31,151 | 21.4 | 1,834 | 41,843 | 21.8 |
| Operating income | 10,573 | 6.8 | 9,158 | 6.3 | 1,414 | 10,404 | 5.4 |
| Non-operating income | 2,447 | 1.5 | 756 | 0.5 | 1,691 | 849 | 0.4 |
| Interest income | 112 |  | 89 |  | 22 | 124 |  |
| Dividend income | 503 |  | 203 |  | 299 | 204 |  |
| Exchange gain | 1,407 |  | 221 |  | 1,186 | 173 |  |
| Others | 424 |  | 241 |  | 182 | 346 |  |
| Non-operating expenses | 2,062 | 1.3 | 1,949 | 1.3 | 113 | 2,567 | 1.3 |
| Interest expenses | 1,160 |  | 1,228 |  | (68) | 1,594 |  |
| Equity in losses of affiliates | 495 |  | 558 |  | (63) | 741 |  |
| Others | 407 |  | 162 |  | 245 | 231 |  |
| Recurring income | 10,957 | 7.0 | 7,964 | 5.5 | 2,993 | 8,685 | 4.5 |
| Extraordinary gains | $\underline{65}$ | 0.1 | 1,231 | 0.8 | $(1,166)$ | 1,245 | 0.6 |
| Reversion of allowance for doubtful accounts | 6 |  | 55 |  | (49) | 52 |  |
| Governmental subsidies | 19 |  | - |  | 19 | - |  |
| Gain on sale of investment securities | 17 |  | 1,108 |  | $(1,090)$ | 1,108 |  |
| Others | 22 |  | 67 |  | (45) | 84 |  |
| Extraordinary losses | 2,651 | 1.7 | $\underline{534}$ | 0.4 | 2,117 | 1,271 | 0.6 |
| Loss on sale and disposal of fixed assets | 247 |  | 143 |  | 104 | 368 |  |
| Impairment loss on fixed assets | 1,920 |  | - |  | 1,920 | - |  |
| Loss on disposal of inventories | 109 |  | 22 |  | 86 | 167 |  |
| Abnormal manufacturing cost | 132 |  | 247 |  | (114) | 344 |  |
| Amortization of retirement benefit obligation at transition |  |  | 57 |  | (57) | 76 |  |
| Severance payment | 110 |  | - |  | 110 | - |  |
| Others | 131 |  | 63 |  | 68 | 314 |  |
| Net income before adjustment of taxes | 8,371 | 5.4 | 8,662 | 5.9 | (290) | 8,659 | 4.5 |
| Corporate, inhabitants and enterprise taxes | 4,197 | 2.7 | 4,348 | 2.9 | (150) | 4,900 | 2.5 |
| Adjustment for deferred taxes | (321) | (0.2) | (183) | (0.1) | (138) | (653) | (0.3) |
| Minority share in net loss of consolidated subsidiaries | 115 | 0.1 | 186 | 0.1 | (71) | 106 | 0.1 |
| Net income | 4,610 | 3.0 | 4,684 | 3.2 | (73) | 4,518 | 2.4 |

(Note) Increase (decrease) represents the comparison between the nine months ended December 31, 2005 and the nine months ended December 31, 2004.

## Consolidated Statements of Cash Flows

| Account Period | Nine months ended December 31,2005 | Nine months ended December 31,2004 | Fiscal Year ended March 31, 2005 |
| :---: | :---: | :---: | :---: |
|  | Amount | Amount | Amount |
| Cash flows from operating activities |  |  |  |
| Net income before adjustment for taxes | 8,371 | 8,662 | 8,659 |
| Depreciation and amortization | 8,982 | 7,429 | 10,265 |
| Impairment loss on fixed assets | 1,920 | - | - |
| Amortization of consolidation adjustments | 20 | 51 | 51 |
| Equity in loss of an affiliate | 495 | 558 | 741 |
| Increase (decrease) in allowance for doubtful ac | (1) | 61 | 57 |
| Interest and dividend income | (616) | (293) | (329) |
| Interest expenses | 1,160 | 1,228 | 1,594 |
| Exchange loss (gain) | (994) | (131) | 413 |
| Decrease (increase) in trade receivables | $(6,086)$ | $(1,722)$ | 1,329 |
| Decrease (increase) in inventories | $(4,932)$ | (657) | $(1,158)$ |
| Increase (decrease) in trade payables | 2,230 | 1,233 | 76 |
| Decrease (increase) in other assets | (860) | (846) | (191) |
| Increase (decrease) in other liabilities | (867) | $(1,231)$ | 1,160 |
| Bonuses to directors and corporate auditors | (107) | (86) | (86) |
| Other non-operating income/expense and extraordinary income/losses | 283 | (934) | (591) |
| Subtotal | 8,999 | 13,322 | 21,992 |
| Interest and dividends received | 516 | 213 | 249 |
| Interest paid | $(1,226)$ | $(1,408)$ | $(1,681)$ |
| Other revenues | 704 | 457 | 647 |
| Other expenditures | (361) | (341) | (759) |
| Income taxes paid | $(5,540)$ | $(3,080)$ | $(3,072)$ |
| Cash flows from operating activities | 3,092 | 9,163 | 17,375 |
| Cash flows from investing activities |  |  |  |
| Deposits in time deposits | $(3,461)$ | $(3,240)$ | $(4,058)$ |
| Proceeds from time deposits | 3,266 | 2,943 | 4,622 |
| Payments for acquisition of securities | $(9,501)$ | (119) | (120) |
| Proceeds from sales of securities | 3,125 | 1,737 | 1,737 |
| Payments for acquisition of newly consolidated subsidiary | (26) | - | - |
| Payments for acquisition of fixed assets | $(14,331)$ | $(11,015)$ | $(15,070)$ |
| Proceeds from sales of fixed assets | 178 | 146 | 206 |
| Lending of loans | (343) | (2) | (2) |
| Collections of loans receivable | 96 | 37 | 57 |
| Payments for other investments | (66) | - | - |
| Proceeds from other investments | 0 | 0 | 0 |
| Cash flows from investing activities | $(21,064)$ | $(9,512)$ | $(12,627)$ |
| Cash flows from financing activities |  |  |  |
| Net increase (decrease) in short-term borrowings | 5,781 | 5,077 | 1,483 |
| Net increase (decrease) in commercial paper | 2,000 | 500 | 500 |
| Proceeds from long-term borrowings | 10,510 | 21,896 | 24,599 |
| Repayment of long-term borrowings | $(7,836)$ | $(6,610)$ | $(9,144)$ |
| Proceeds from issuance of bonds |  | 2,979 | 2,979 |
| Payments for redemption of bonds | (10) | $(10,000)$ | $(10,000)$ |
| Payments for issuance of stock | (7) | - | - |
| Proceeds from disposal of treasury stock | 0 | - | - |
| Payments for acquisition of treasury stock | (48) | (48) | (80) |
| Proceeds from sale and lease back | 69 | - | ) |
| Repayments of finance lease obligation | (274) | (292) | (391) |
| Payments for dividends | $(1,821)$ | $(2,835)$ | $(2,858)$ |
| Cash flows from financing activities | 8,362 | 10,666 | 7,088 |
| Effect of exchange rate changes on cash and cash equivalents | 901 | 72 | (349) |
| Increase (decrease) in cash and cash equivalents | $(8,709)$ | $(10,389)$ | 11,486 |
| Balance of cash and cash equivalents at the beginning of the period | 53,734 | 42,228 | 42,228 |
| Balance of cash and cash equivalents in new consolidated subsidiary at the beginning of the period | 141 | 19 | 19 |
| Balance of cash and cash equivalents at the end of the period | 45,166 | 52,638 | 53,734 |

(Segment information)

1. Segment information by business category
(1)Nine months ended December 31, 2005 (From April 1, 2005 to December 31, 2005)
(Millions of yen)

|  | Medical | Pharma- <br> Ceutical |  <br> Materials | Super- <br> market | Other | Total | Eliminations <br> /Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales and operating <br> income <br> Net sales |  |  |  |  |  |  |  |  |
| (1) Sales to third parties <br> (2) Inter-segment sales <br> and transfers | 67,944 | 26,205 | 8,696 | 52,218 | 982 | 156,047 | - | 156,047 |
| Total | - | - | 2,557 | 25 | 385 | 2,967 | $(2,967)$ | - |
| Operating expenses | 67,944 | 26,205 | 11,253 | 52,243 | 1,367 | 159,015 | $(2,967)$ | 156,047 |
| Operating income | 10,721 | 1,821 | 1,275 | 544 | 451 | 14,814 | $(4,241)$ | 10,573 |

(2) Nine months ended December 31, 2004 (From April 1, 2004 to December 31, 2004)
(Millions of yen)

|  | Medical | Pharmaceutical |  <br> Materials | Supermarket | Other | Total | Eliminations /Corporate | Consolidated |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales and operating income Net sales <br> (1) Sales to third parties <br> (2) Inter-segment sales and transfers | $\begin{array}{r} 62,535 \\ 695 \end{array}$ | 19,516 | $\begin{aligned} & 8,667 \\ & 1,753 \end{aligned}$ | $\begin{array}{r} 54,164 \\ 24 \end{array}$ | $\begin{aligned} & 847 \\ & 425 \end{aligned}$ | $\begin{array}{r} 145,732 \\ 2,898 \end{array}$ | $(2,898)$ | $145,732$ |
| Total | 63,230 | 19,516 | 10,421 | 54,189 | 1,272 | 148,631 | $(2,898)$ | 145,732 |
| Operating expenses | 53,998 | 17,643 | 8,987 | 53,993 | 1,060 | 135,682 | 891 | 136,574 |
| Operating income | 9,232 | 1,873 | 1,434 | 196 | 211 | 12,948 | $(3,790)$ | 9,158 |

(3)Fiscal Year ended March 31, 2005 (From April 1, 2004 to March 31, 2005)

|  | Medical | Pharma- <br> ceutical |  <br> Materials | Super- <br> market | Other | Total | Eliminations <br> /Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales and operating <br> income <br> Net sales |  |  |  |  |  |  |  |  |
| (1) Sales to third parties <br> (2) Inter-segment sales <br> and transfers | 82,503 | 26,207 | 11,666 | 70,841 | 1,101 | 192,320 | - | 192,320 |
| Total | 876 | - | 2,384 | - | 553 | 3,813 | $(3,813)$ | - |
| Operating expenses | 83,379 | 26,207 | 14,051 | 70,841 | 1,654 | 196,133 | $(3,813)$ | 192,320 |
| Operating income | 11,039 | 2,260 | 23,946 | 12,162 | 70,726 | 1,366 | 180,541 | 1,374 |

Note: 1. Classification of business categories and main products in each business category Business categories are classified based on the proximity in terms of purposes and manners of usage of the products in the market.
Main products belonging to each business categories are as follows

| Business <br> category | Main products |
| :--- | :--- |
| Medical | Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets, <br> etc. |
| Pharmaceutical | Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysate <br> solution, and circulatory drugs, etc. |
| Glass \& Materials | Glass for pharmaceutical containers, glass for thermos bottles, glass for <br> lighting purposes, stoppers for plastic containers and rubber stoppers, etc. |
| Supermarket | Fresh meat and fish, vegetables, fruits, processed food, daily foods, frozen <br> foods, general groceries and medicine, etc. |
| Other | Machinery for manufacture of medical equipment and real estate rental <br> income, etc. |

2. Operating expenses of "Eliminations/Corporate" for the nine months ended December 31, 2005, the nine months ended December 31, 2004 and the fiscal year ended March 31, 2005 included unallocated corporate costs of 4,241 million yen, 3,790 million yen and 5,188 million yen, respectively. The unallocated corporate costs consisted primarily of the parent companies' research and development costs and headquarters administration costs.
3. Segment information by geographical area
(1)Nine months ended December 31, 2005 (From April 1, 2005 to December 31, 2005)
(Millions of yen)

|  | Japan | America | Europe | Asia | Total | Eliminations <br> /Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales and operating <br> income <br> Net sales |  |  |  |  |  |  |  |
| (1) Sales to third parties <br> (2) Inter-segment sales <br> and transfers | 139,593 | 10,915 | 4,510 | 1,028 | 156,047 | - | 156,047 |
| Total | 12,075 | 326 | 4 | 8,017 | 20,423 | $(20,423)$ | - |
| Operating expenses | 131,668 | 11,241 | 4,515 | 9,045 | 176,471 | $(20,423)$ | 156,047 |
| Operating income (loss) | 15,097 | $(260)$ | $(140)$ | 563 | 15,259 | $(4,686)$ | 10,573 |

(2) Nine months ended December 31, 2004 (From April 1, 2004 to December 31, 2004)
(Millions of yen)

|  | Japan | America | Europe | Asia | Total | Eliminations <br> /Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales and operating <br> income <br> Net sales |  |  |  |  |  |  |  |
| (1) Sales to third parties <br> (2) Inter-segment sales <br> and transfers | 133,050 | 7,513 | 4,320 | 848 | 145,732 | - | 145,732 |
| Total | 9,448 | 245 | 2 | 7,518 | 17,214 | $(17,214)$ | - |
| Operating expenses | 142,499 | 7,759 | 4,322 | 8,366 | 162,947 | $(17,214)$ | 145,732 |
| Operating income (loss) | 129,786 | 7,909 | 4,496 | 7,851 | 150,044 | $(13,469)$ | 136,574 |

(3)Fiscal Year ended March 31, 2005 (From April 1, 2004 to March 31, 2005)
(Millions of yen)

|  | Japan | America | Europe | Asia | Total | Eliminations <br> /Corporate | Consolidated |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales and operating <br> income <br> Net sales |  |  |  |  |  |  |  |
| (1) Sales to third parties <br> $(2)$ Inter-segment sales <br> and transfers | 175,327 | 9,790 | 5,816 | 1,385 | 192,320 | - | 192,320 |
| Total | 12,261 | 384 | 3 | 10,012 | 22,662 | $(22,662)$ | - |
| Operating expenses | 171,827 | 10,699 | 6,166 | 10,634 | 199,327 | $(17,411)$ | 181,915 |
| Operating income (loss) | 15,762 | $(523)$ | $(346)$ | 762 | 15,655 | $(5,251)$ | 10,404 |

Note: 1. Classification of countries or areas is based on geographical proximity.
2. The major countries and areas included in each geographical area are as follows

America ........ The United States of America and Brazil
Europe ......... Belgium
Asia $\qquad$ China and Thailand
3. Operating expenses of "Eliminations and Corporate" for the nine months ended December 31, 2005, the nine months ended December 31, 2004 and the fiscal year ended March 31, 2005 included unallocated corporate costs of 4,241 million yen, 3,790 million yen and 5,188 million yen, respectively. The unallocated corporate costs consisted primarily of the parent company's research and development costs and the headquarters administration costs.

## 3. Overseas sales

(1)Nine months ended December 31, 2005 (From April 1, 2005 to December 31, 2005) (Millions of yen)

|  | America | Europe | Asia | Total |
| :--- | :---: | :---: | :---: | :---: |
| 1. Overseas sales | 28,417 | 14,894 | 4,547 | 47,860 |
| 2. $\quad$ Consolidated net sales |  |  |  |  |
| 3.Percentage of overseas sales <br> against consolidated net <br> sales (\%) | $18.2 \%$ | $9.6 \%$ | $2.9 \%$ | 156,047 |

(2) Nine months ended December 31, 2004 (From April 1, 2004 to December 31, 2004)

|  | America | Europe | Asia | Total |
| :--- | ---: | ---: | ---: | ---: |
| 1.Overseas sales | 22,827 | 13,763 | 3,872 | 40,463 |
| 2. $\quad$ Consolidated net sales |  |  |  |  |
| 3.Percentage of overseas sales <br> against consolidated net <br> sales (\%) | $15.7 \%$ | $9.4 \%$ | $2.7 \%$ | 145,732 |

(3)Fiscal Year ended March 31, 2005 (From April 1, 2004 to March 31, 2005)
(Millions of yen)

|  | America | Europe | Asia | Total |
| :---: | :---: | :---: | :---: | :---: |
| 1. Overseas sales | 29,953 | 18,313 | 5,234 | 53,502 |
| 2. Consolidated net sales |  |  |  | 192,320 |
| 3. Percentage of overseas sales against consolidated net sales (\%) | 15.6\% | 9.5\% | 2.7\% | 27.8\% |

Note: 1. Classification of countries or areas is based on geographical proximity.
2. The major countries and areas included in each geographical area are as follows

America ........ The United States of America, Canada and Brazil
Europe ......... Belgium, Denmark and Germany
Asia ............ China, Taiwan and Thailand
3. Overseas sales represent those of the Company and the consolidated subsidiaries to countries and areas outside of Japan.

## Production, Orders received and Sales

## 1.Production

(Millions of yen)

| Business segment | Nine months ended December 31, 2005 |  | Nine months ended December 31, 2004 |  | Fiscal year ended March 31, 2005 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount Produced | Ratio against the same period of the previous fiscal year (\%) | Amount Produced | Ratio against the same period of the previous fiscal year (\%) | Amount Produced | Ratio against the same period of the previous fiscal year (\%) |
| Medical | 49,853 | 11.7 | 44,632 | 3.6 | 58,921 | 2.3 |
| Pharmaceutical | 26,678 | 39.4 | 19,132 | 1.5 | 25,479 | 2.8 |
| Glass \& Materials | 2,491 | 2.7 | 2,426 | (12.9) | 3,668 | (4.2) |
| Other | 489 | 5.2 | 465 | (11.8) | 493 | (31.5) |
| Total | 79,513 | 19.3 | 66,656 | 2.2 | 88,563 | 1.9 |

Note: 1. Amounts produced are calculated based on average selling prices.
2. The above amounts are after eliminations of the intersegment transactions.
3. The above amounts do not include the related consumption taxes.

## 2. Orders received

Since we adopt the production system based on estimated orders, there is nothing applicable hereto regarding the amount and the balance of orders received.
3. Sales

| Business segment | Nine months ended December 31, 2005 |  | Nine months ended December 31, 2004 |  | Fiscal year ended March 31, 2005 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount Produced | Ratio against the same period of the previous fiscal year (\%) | Amount Produced | Ratio against the same period of the previous fiscal year (\%) | Amount Produced | Ratio against the same period of the previous fiscal year (\%) |
| Medical | 67,944 | 8.6 | 62,535 | 6.2 | 82,503 | 4.8 |
| Pharmaceutical | 26,205 | 34.3 | 19,516 | 2.0 | 26,207 | 3.4 |
| Glass \& Materials | 8,696 | 0.3 | 8,667 | (0.8) | 11,666 | (1.9) |
| Supermarket | 52,218 | (3.6) | 54,164 | (0.5) | 70,841 | (0.7) |
| Other | 982 | 16.0 | 847 | (21.4) | 1,101 | (20.6) |
| Total | 156,047 | 7.1 | 145,732 | 2.4 | 192,320 | 1.9 |

Note: 1. The above amounts are after eliminations of the intersegment transactions.
2. The above amounts do not include the related consumption taxes.

